Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT HEMATOLOGIC MALIGNANCIES

NCT00953758 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00953758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00953758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT HEMATOLOGIC MALIGNANCIES
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
March 3, 2010
Completion date
February 27, 2013
Enrollment
47 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies